POLITICS - Mono Scoops - Your goto app for Global Awareness

A post-hoc analysis of the TRIDENT trial, presented at the American Heart Association's Scientific Sessions 2026, found the low-dose triple pill GMRx2 reduced recurrent stroke risk irrespective of kidney function in people with prior intracerebral haemorrhage, with serious adverse events balanced overall and numerically lower with GMRx2 at the lowest kidney function.

MAR001, a monoclonal antibody blocking ANGPTL4, cut fasting triglycerides by a placebo-adjusted 39.1% to 45.5% at week 12 across three doses in the 235-person Phase 2b TYDAL-TIMI 78 trial, with no worsening of blood sugar control; results were presented at AHA 2026 and published simultaneously in the New England Journal of Medicine.

CRISPR Therapeutics reported Phase 1b data for CTX310, its one-time in vivo CRISPR/Cas9 therapy targeting ANGPTL3: a single infusion cut triglycerides by a mean 63% and ANGPTL3 by 65% at Day 30 in ten people with severe hypertriglyceridemia, with no treatment-related serious adverse events.

Marengo reported interim STARt-002 results showing its T-cell agonist invikafusp alfa plus sacituzumab govitecan shrank tumours in 71% of assessable metastatic breast cancer patients, with confirmed complete responses in both triple-negative and hormone-receptor-positive disease.

Medicenna reported a 40% response rate for its IL-2 Superkine MDNA11 in biomarker-enriched gastrointestinal cancers that had resisted prior immunotherapy, with all liver lesions regressing in four monotherapy patients and durable activity also seen in advanced melanoma.

Valneva announced positive results from two Phase 2 trials of its tetravalent Shigella vaccine candidate S4V2: an infant trial in Kenya showed strong antibody responses across all four targeted serotypes, and a controlled human infection trial in the United States met its primary endpoint.

UCB and Biogen presented new post-hoc data at ACR Convergence 2026 showing dapirolizumab pegol beat placebo on a novel lupus response measure, TRM-SLE, in the Phase 3 PHOENYCS GO trial, with more patients also sustaining low disease activity.

Vir Biotechnology said its monthly elebsiran and tobevibart combination met all endpoints in the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis delta, with 44% of patients reaching undetectable virus plus normal liver enzymes at week 48, and expanded Phase 2 data showed all 28 patients completing 96 weeks reached undetectable virus.

Samsung Bioepis said its Keytruda biosimilar SB27 matched the original drug in a global Phase 3 trial in 555 lung cancer patients, presenting the full dataset at SITC 2026 in Phoenix, after filing for approval in South Korea in August and with the US FDA in October.

Health Canada warned against unauthorized injectable peptides sold online after tests found bacteria in products from a Chinese supplier, seizing more than 11,400 vials from the supplier and two Canadian retailers.

Novo Nordisk said a post hoc analysis of its phase 3 ESSENCE trial found weekly semaglutide 2.4 mg improved liver injury, disease activity and fibrosis markers at 72 weeks in MASH patients with a BMI below 27.

Johnson & Johnson reported first Phase 1 results for pasritamig plus JNJ-9401 in advanced prostate cancer: 11 of 15 patients at the recommended regimen had PSA falls of at least 50 percent, but the readout is small and preliminary, with a Phase 3 trial already under way.